Table 1 Characteristics of the studies included in the meta-analysis
Year | Author | Blood Sampling Schedule | Patients | Age, y C/CTL | Sample size C/CTL | Treatment modality | Definition of MACEs | Measuring Methods | Rates of HF C/CTL | Follow up |
|---|---|---|---|---|---|---|---|---|---|---|
2016 | HAMID | 24 h | STEMI | 57/53 | 17/61 | PCI, Thrombolytic | All-cause mortality, recurrent nonfatal MI, or HF and the secondary endpoint of early adverse LV remodeling | ELISA | NR | 30 days |
2015 | Liu | Admission | STEMI | 58/60 | 30/102 | PCI | Recurrent MI, heart failure readmission, unplanned repeat revascularization, malignant dysrhythmia, stroke, or pulmonary embolism | ELISA | NR | 1 year |
2013 | Leu | Admission | CAD | 68/67 | 33/42 | Antiplatelet | CV death, nonfatal AMI, unstable angina, stroke, transient ischemic attack, or peripheral arterial occlusive disorder | ELISA | NR | 40 months |
2013 | Hyseni | Admission | ACS | 67.5/ 76.8 | 293/46 | PCI, Antithrombotic | All-cause mortality | ELISA | NR | 4 years |
2008 | Yu | Admission, 12 h, 48 h | ACS | 68/64 | 22/48 | Anticoagulation | Death, MI or recurrent MI, and recurrent angina | ELISA | NR | 30 days |
2008 | BOOS | 24 h | ACS | 69/60.6 | 42/169 | Thrombolysis, PCI | CV death, non-fatal MI, readmission with acute HF and stroke, and CV death separately. | ELISA | 28.6 / 7.6 | 338 days |
2006 | Fuchs | 24 h | ACS | 60/57 | 58/150 | PCI, Thrombolysis | Recurrent non-fatal MI (STEMI and NSTE-MI) | Turbidometry | NR | 28 months |
2006 | An | 24 h | ACS | NR | 21/59 | NR | Non-fatal reinfarction, non-fatal heart failure, recurrent angina attacks, drug intensification or emergency revascularization, and cardiac death | ELISA | NR | 30 days |
2005 | Lee | Admission, 48 h | ACS | 67/70 | 24/34 | Antiplatelet, Anticoagulation | Death, MI, and refractory angina requiring revascularisation | ELISA | 8 /6 | 30 days |
2005 | Warlo | 24 h | CAD | NR | 73/927 | Antiplatelet | Unstable angina pectoris, MI, non haemorrhagic stroke and death | NR | NR | 2 years |
2003 | Niessner | Admission | CAD | 56/52 | 103/38 | NR | All-cause mortality and MI, revascularization procedures including PTCA with/without coronary stenting and ACBG. | ELISA | NR | 13 years |
2002 | Eikelboom | Admission | ACS | NR | 78/407 | Anticoagulant, Antiplatelet | CV death, MI, stroke or refractory ischaemia | NR | NR | 30 days |
2000 | Redondo | Admission | CAD | 59/57 | 37/157 | NR | Fatal MI, non-fatal MI, percutaneous transluminal coronary angioplasty or CABG. | ELISA | NR | 2 years |
1999 | Moss | Admission | MI | 59/47 | 81/964 | NR | Death due to coronary heart disease or recurrent nonfatal MI | ELISA | NR | 26 months |
1998 | Montalescot | Admission, 48 h | CAD | 70/70 | 48/20 | Antiplatelet | Death, MI, recurrent angina, or revascularization | ELISA | NR | 30 days |